Liminatus Pharma Corp - רווח נקי למניה בארבעת הרבעונים האחרונים LIMN

Liminatus Pharma is implementing ESG standards in the development of antitumor agents, reducing laboratory emissions and adhering to testing ethics. The business relies on CAR-T innovations for personalized therapy for gastrointestinal cancers. The confirmed price history on the chart reflects EPS (TTM) dynamics at -107.20. The company is currently implementing robotic molecule screening and software automation for clinical data analysis to accelerate drug release.
LIMN (Liminatus Pharma LLC): פילוחים אנליטיים ודוחות לפי אינדיקטורים

This indicator measures the dynamics of net earnings per share on a rolling year basis, allowing investors to assess business scaling rates and capital management efficiency. When analyzing YoY EPS changes on a rolling 12-month basis via the GURU.Markets platform, profitability peaks should be correlated with the full operational readiness of production capacities and the loading schedule of Liminatus Pharma (LIMN) oncology laboratories.